An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab (AMG 162) in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-Metastatic Prostate Cancer

This study is ongoing, but not recruiting participants.

Study NCT00838201 Information provided by Amgen

First Received: February 5, 2009 Last Updated: August 25, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	September 2012
Primary Completion Date:	May 2010 (Final data collection date for primary outcome measure)